Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
71 hedge funds and large institutions have $22.2M invested in Eiger BioPharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 21 reducing their positions, and 16 closing their positions.
650% more call options, than puts
Call options by funds: $105K | Put options by funds: $14K
24% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 21
12% less funds holding
Funds holding: 81 → 71 (-10)
25% less capital invested
Capital invested by funds: $29.5M → $22.2M (-$7.22M)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$4M |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$1.7M |
| 3 |
6CM
683 Capital Management
New York
|
+$1.29M |
| 4 |
Renaissance Technologies
New York
|
+$249K |
| 5 |
JP Morgan Chase
New York
|
+$183K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$2.47M |
| 2 |
Morgan Stanley
New York
|
-$1.17M |
| 3 |
Millennium Management
New York
|
-$1.17M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$747K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$449K |
EIGR Hedge Fund Activity: Q1 2023 in Review
71 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q1 2023, worth a combined $22.2M — down 25% from $29.5M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of EIGR and 8 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 26 added.
The largest buyer was Ameriprise, adding an estimated $4M. The largest seller was Barclays, cutting an estimated $2.47M.
- 71 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q1 2023, down from 81 in Q4 2022.
- Funds reported $22.2M of Eiger BioPharmaceuticals, Inc. stock for Q1 2023, down 25% quarter-over-quarter.
- 8 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q1 2023 and 16 closed out, a net change of -8 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q1 2023 was Ameriprise, an estimated $4M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q1 2023 was Barclays, an estimated $2.47M sold.
Based on aggregated 13F filings for Q1 2023.